Conflict of Interest: Nothing to report.
Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study†
Article first published online: 30 DEC 2010
Copyright © 2011 Wiley-Liss, Inc.
Pediatric Blood & Cancer
Volume 57, Issue 1, pages 36–40, 15 July 2011
How to Cite
Taga, T., Shimomura, Y., Horikoshi, Y., Ogawa, A., Itoh, M., Okada, M., Ueyama, J., Higa, T., Watanabe, A., Kanegane, H., Iwai, A., Saiwakawa, Y., Kogawa, K., Yamanaka, J. and Tsurusawa, M. (2011), Continuous and high-dose cytarabine combined chemotherapy in children with down syndrome and acute myeloid leukemia: Report from the Japanese children's cancer and leukemia study group (JCCLSG) AML 9805 down study. Pediatr. Blood Cancer, 57: 36–40. doi: 10.1002/pbc.22943
- Issue published online: 9 MAY 2011
- Article first published online: 30 DEC 2010
- Manuscript Accepted: 5 NOV 2010
- Manuscript Received: 2 SEP 2010
- Clinical trials;
- Down syndrome
The aim of the JCCLSG AML 9805 Down study was to evaluate the effect of continuous and high-dose cytarabine combined chemotherapy on the survival outcome of acute myeloid leukemia (AML) with Down syndrome (DS).
From May 1998 to December 2006, DS patients with newly diagnosed AML were enrolled. Remission induction therapy consisted of two courses of pirarubicin, vincristine, and continuous-dose cytarabine (AVC1). The patients who achieved complete remission (CR) after two courses of AVC1 were subsequently treated with mitoxantrone and continuous-dose cytarabine (MC), etoposide and high-dose cytarabine (EC) and pirarubicin, vincristine, and continuous-dose cytarabine (AVC2).
Twenty-four patients were enrolled. All patients were younger than 4 years and diagnosed as having acute megakaryoblastic leukemia. Twenty-one patients achieved CR. Three patients died during remission induction therapy due to serious infection. No toxic deaths were observed during remission. All but one patient maintained CR without serious complications. The 5-year overall and event-free survivals were 87.5% ± 6.8% and 83.1% ± 7.7%, respectively.
Continuous and high-dose cytarabine combined chemotherapy with reduced intensity would be effective in DS children with AML. Pediatr Blood Cancer 2011;57:36–40. © 2011 Wiley-Liss, Inc.